## Pharmacy Pre-Authorization Criteria

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>Psoriasis Topicals</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dovonex Cream/Foam (calcipotriene 0.005%)</td>
</tr>
<tr>
<td></td>
<td>Enstilar Foam (calcipotriene/betamethasone dipropionate)</td>
</tr>
<tr>
<td></td>
<td>Sorilux Foam (calcipotriene 0.005%)</td>
</tr>
</tbody>
</table>

### Policy #

| 13141 |

### Indications

- **Enstilar Foam**, **Sorilux Foam**, and **Dovonex Cream** are FDA approved for the treatment of plaque psoriasis in patients 18 years and older.
- **Dovonex Solution** is indicated for the topical treatment of chronic, moderately severe psoriasis of the scalp.

### Criteria

ConnectiCare considers **Enstilar Foam** to be medically necessary when the following criteria are met:

1. Patient is diagnosed with plaque psoriasis
   AND
2. Patient has had an adequate trial (of 2 weeks’ duration) of any one of the following:
   - Taclonex Suspension/Ointment (calcipotriene/betamethasone)
   - Dovonex Cream (calcipotriene cream)
   - Calcipotriene ointment
   - Calcipotriene Solution
   - Sorilux Foam

ConnectiCare considers **Dovonex Cream and Sorilux Foam** to be medically necessary for patients who meet all of the following criteria:

- Patient has clinically documented plaque psoriasis
- Patient has a documented intolerance to, or treatment failure of an adequate trial of calcipotriene solution, ointment or cream

ConnectiCare considers **Dovonex Solution** to be medically necessary for patients who meet all of the following criteria:

- Patient has clinically documented plaque psoriasis of the scalp
- Patient has a documented intolerance to, or treatment failure of an adequate trial of calcipotriene solution, ointment or cream

### Drug(s)

<table>
<thead>
<tr>
<th>Psoriasis Topicals</th>
</tr>
</thead>
<tbody>
<tr>
<td>#13141</td>
</tr>
</tbody>
</table>
**LIMITATIONS**

- If approved, approval for Enstilar Foam will be granted for 12 weeks only.
- If the above criteria are met for Dovonex or Sorilux, authorization is limited to no more than 8 weeks. If no improvement is seen within 8 weeks, reassessment of the diagnosis may be necessary.

**REFERENCES**

1. Sorilux® foam full prescribing information. Stiefel Laboratories, Research Triangle Park, NC.
2. Dovonex package insert, LEO Laboratories, LTD, Dublin, Ireland
3. Enstilar package insert, LEO Pharma, 1 Sylvan Way, Parsippany, NJ 07054

**P&T REVIEW HISTORY**

10/12, 10/13, 10/14, 11/15, 5/16, 8/17, 7/18

**REVISION RECORD**

4/13, 8/16,